Microbiome-based interventions to modulate gut ecology and the immune system

Thomas C. A. Hitch1, Lindsay J. Hall2,3,4, Sarah Kate Walsh5,6, Gabriel E. Leventhal7, Emma Slack8, Tomas de Wouters7, Jens Walter6 and Thomas Clavel1,8

© The Author(s) 2022

The gut microbiome lies at the intersection between the environment and the host, with the ability to modify host responses to disease-relevant exposures and stimuli. This is evident in how enteric microbes interact with the immune system, e.g., supporting immune maturation in early life, affecting drug efficacy via modulation of immune responses, or influencing development of immune cell populations and their mediators. Many factors modulate gut ecosystem dynamics during daily life and we are just beginning to realize the therapeutic and prophylactic potential of microbiome-based interventions. These approaches vary in application, goal, and mechanisms of action. Some modify the entire community, such as nutritional approaches or faecal microbiota transplantation, while others, such as phage therapy, probiotics, and prebiotics, target specific taxa or strains. In this review, we assessed the experimental evidence for microbiome-based interventions, with a particular focus on their clinical relevance, ecological effects, and modulation of the immune system.

Mucosal Immunology (2022) 15:1095–1113; https://doi.org/10.1038/s41385-022-00564-1

INTRODUCTION
To fully appreciate the stakes and challenges of microbiome-based interventions, it is important to detail a few important features of gut microbiomes, which is done in this introductory section.

The gut microbiome is a highly complex ecosystem
The human body is colonised by rich communities of microorganisms at various body sites, with the gastrointestinal tract being home to a cell-rich and diverse community. The intestinal microbiome consists of various types of eukaryotic (fungi, helminths and protozoa1) and prokaryotic (bacteria and archaea)2 microbes, as well as viruses1. While protozoa and helminths are frequent colonisers of the gut within developing nations, their prevalence is significantly reduced in developed countries, leading to them being understudied4. Both groups have generally been viewed as pathogenic in nature within the human gut, however they have been shown to interact with the gut microbiome and influence the enteric immune system4, as well as wider allergic inflammation6. Bacteria within the gut have been extensively studied and will be the major topic of this review. Due to the complexity and highly dynamic nature of enteric microbial populations, study of their interactions with the host is made difficult.

With the emergence of large population-based studies from different continents, our understanding of the diverse landscape within the human gut continues to expand4. While the human gut may represent a total diversity of ~2000 bacterial species8 and almost 200,000 phages3, an individual’s gut is likely home to a few hundred bacterial species, although sequencing methods can only detect 100–200 within an individual sample9,16. The core human gut microbiome, which are species found in the majority of individuals, consists of less than one hundred out of the thousands of bacterial species found in the intestine10. Although these dominant species constitute 99% of the mapped reads in sequencing studies of the human microbiome11, each of these core species may be represented by different strains with functional differences, further contributing to the complexity of gut microbiomes12,13. Currently it remains unclear how strain-level diversity detected by sequencing translates into physiological differences that are of relevance for functional variations of the entire community between individuals. These issues are further confounded due to much of this variation occurring within species and genes of unknown function14,15.

The complex, yet stable gut microbial ecosystem in adults contrasts dramatically with the rapid seeding of the sterile intestinal tract of new-borns. This rapid process of colonisation makes early life an important period during which both the ecosystem trajectory and immune responses are shaped.

The perinatal period is crucial for establishment of microbial-host interactions
The perinatal period is defined as pregnancy and up to one year post birth and is a time of immense physiological programming
that influences health. Although previous studies have suggested an in utero (fetal) and placental microbiome during healthy pregnancies, the detected bacterial 'communities' are likely the result of contamination, either during DNA extraction (through contamination of reagents and purification columns), tissue collection, and/or during the sample processing and sequencing\(^\text{6,17}\). Those microbes that have been definitely identified in these otherwise sterile sites include those associated with negative birth outcomes, such as *Streptococcus agalactiae*\(^\text{16}\). Gut microbes do play a key role in foetal development; however, this is via the maternal gut microbiome, with microbial mediators and metabolites entering the circulation and impacting particular developmental and immune pathways in utero (see sections below)\(^\text{19}\). Interestingly, the maternal gut microbiome alters during pregnancy, including reduction in diversity over the course of gestation and increasing levels of *Bifidobacterium* in women and mice which appears to be partly driven by progesterone\(^\text{20}\). The direct ecological interactions between the gut microbiome and the infant host starts immediately post birth, as this is when initial seeding, from a range of environments and sources, occurs.

Vertical transmission of microbes from mother to baby during vaginal child birth provides a source of *Bacteroides* and *Bifidobacterium* (from the maternal gut) that shapes the initial ecosystem and longer term profiles\(^\text{21}\). Caesarean section delivery (CSD) can interrupt this microbial transfer, and these infants are often characterised by a delay in the acquisition of these commensals, and increased levels of hospital acquired bacteria that may also be multi-drug resistant\(^\text{22}\). As gut bacteria are dependent on the host diet, a diet solely comprising maternal milk drives a *Bifidobacterium* dominant profile (between 50–90% of the total community). This is due to the enzymatic machinery encoded by specific strains of *Bifidobacterium* that are able to break down complex human milk sugars (i.e., human milk oligosaccharides [HMOs]), that are not actively metabolised by the infant\(^\text{23}\). In contrast to the gut microbiome of breast-fed infants, formula-fed infants are characterised by higher microbial diversity and elevated levels of potentially pathogenic organisms, such as *Escherichia coli* and *Clostridiodes difficile* (formerly *Clostridium*), and reduced levels of beneficial *Bifidobacterium*\(^\text{24}\).

The introduction of solid food, paralleled with reduced intake of human milk, and then cessation of breast-feeding during weaning results in another highly dynamic phase of ecosystem maturation and structuring. The ever-expanding nutritional content and oral intake of environmental matter drives the introduction, transient and then longer-term colonisation of horizontally acquired microbes. Genera such as *Veillonella*, *Roseburia*, *Bacteroides*, and members of the *Lachnospiraceae* family begin to establish from month 6 onwards, and although *Bifidobacterium* abundance reduces, there is replacement of strains able to utilise HMOs, with those that are able to use complex plant carbohydrates and starches\(^\text{25}\), leading to the replacement of infant-associated taxa (e.g. *Bifidobacterium longum* subsp. *infantis*) with adult-associated species (such as *Bifidobacterium adolescentis*).

Throughout this perinatal period, the infant gut microbiome is highly dynamic, and therefore more susceptible to microbiome perturbations, which is linked to a plethora of acute and chronic (including immune-mediated) conditions. This is why understanding the ecological principles that govern microbial assembly during this developmental window is important and a prime-time period for beneficially manipulating the gut microbiome to promote appropriate immune development.

**Equilibrium and imbalance within the gut**

The diversity of microbial taxa within an individual's gut microbiome leads to a large range of microbial communities between individuals. It has been suggested that these communities can be grouped into three categories, originally termed 'enterotypes', based on the dominance of species within the genera *Ruminococcus*, *Bacteroides*, or *Prevotella*\(^\text{26,27}\). Since the proposition of enterotypes in 2011, there has been great debate as to if they constitute real 'clusters' of the microbial communities or are driven by artificial clustering. While this matter has been reviewed in greater depth elsewhere\(^\text{28}\), enterotypes do not appear to be stable as an individual's microbiome can swap enterotypes during the course of a year\(^\text{29}\).

While the exact taxa of high importance within the gut are still debated, it is generally agreed that a diverse gut microbiome is beneficial. However, this is a simplistic approach to the microbiome as it is not the diversity of the microbiome per se which is beneficial, but the functions those microbes contribute. In part the association between taxonomic diversity and healthy states is because a diverse community will cover a greater number of functional niches. Furthermore, the interactions between commensal species provide additional benefits that no single species provides on its own.

Despite the apparent simplicity of the gut microbiome that establishes postnatally, important cross-feeding interactions already establish and contribute to the health of the host\(^\text{30}\). *Bifidobacteria* and lactobacilli produce the necessary enzymes to break down the complex milk oligosaccharides into simpler saccharides like lactose or glucose\(^\text{31}\). These simpler sugars are either absorbed by the host, or alternatively further used as an energy source by, for example, fast growing lactic acid bacteria. These produce lactic acid (or lactate in conjugate form), which itself can be metabolised into short-chain fatty acids (SCFA) such as butyrate and propionate\(^\text{32}\). Thus, even in this early phase of dietary homogeneity a trophic food chain of cross-feeding mechanisms between gut bacteria begins to establish\(^\text{33}\).

Disruption of these metabolic interactions between different gut bacteria can result in disease. For example, the production of hydrogen gas by specific types of lactate-utilising bacteria has been postulated to contribute to infant colic\(^\text{34}\). As the host matures and their diet transitions to solid food, the gut microbiome matures and gains in complexity. This introduces a plethora of novel bacteria that each take on different functional roles, termed niches, within a larger metabolic network that converts primary dietary components (mostly complex fibres, see sections below) into resources for growth or end metabolites\(^\text{35}\).

The occupation of these functional niches, as well as their integration within greater metabolic interactions prevent opportunistic pathogens from being able to colonise. This is termed niche exclusion and occurs if a current occupant of the environment already utilises the same substrates as the pathogen, preventing the pathogen accessing the nutrients it requires. This has been shown to occur with *Klebsiella oxytoca* preventing colonisation of *Klebsiella pneumoniae*\(^\text{36}\), and *E. coli* preventing the colonisation of *Salmonella enterica*\(^\text{37}\). In both cases it was the shared utilisation of specific substrates by the resident microbe which prevented colonisation by the invading pathogen. These examples highlight the benefits of a diverse microbiome, as the more diverse the microbiome is, the more functional niches are occupied and the harder it is for pathogens to colonise.

**Biogeography of the gut is important**

The gastrointestinal tract itself is not a homogenous ecosystem but instead consists of a diverse range of environments for microbial species to reside. The small intestine is generally viewed as being sparsely colonised with a limited number of microbial species, which increases towards the distal gastrointestinal tract\(^\text{38,39}\). The limited number of studies that have looked at small intestinal communities suggest the presence of a few dominant taxa such as *Streptococcus*, *Escherichia*, *Gemella*, and *Veillonella* spp.\(^\text{40,41}\). Distally, the colon is home to a more diverse community of microbes that also varies depending on the segment studied\(^\text{42}\).

While it is the luminal content which is generally studied, the mucosal surface is also home to a distinct community of microbes.
compared to that of the lumen. A major component of the mucus layer is mucin, a glycosylated protein which can be utilised by specialised species. While mucus in the small intestine and cecum/proximal colon is unstructured and easily detachable, the distal colon is covered in a double layer of dense mucus, limiting direct microbiome-host interaction. This difference in proximity of the host and microbiome is immunologically relevant, with the small intestine acting as the major site of immune priming. The mucus also acts as a nutrient source used by the microbiome, facilitating a symbiotic relationship between the host and its microbes which is discussed in more detail later within this review. The mucosal-associated microbiome is enriched with members of Bacteroidaceae, Lachnospiraceae, Akkermansia muciniphila, and Enterococcus gallinarum. Similar to the lumen, the mucosal microbiome varies greatly across gut locations, sharing <60% of species across its length. These differences in composition along the gastrointestinal tract are driven by a range of factors, including the availability of substrates, pH of the environment, and partial pressure of oxygen. Simple sugars are absorbed quickly from the fast-flowing content within the small intestine, and oligosaccharides are utilised quickly by the dominant taxa present including lactobacilli, while longer-chain dietary fibres are fermented within the slow-flowing content of the colon. Colonic fibre fermentation is conducted by a diverse community of species, each containing a unique repertoire of carbohydrate utilisation enzymes which work in tandem to release substrates, forming trophic chains. Most bacterial species within the human gut are strict anaerobes. Small amounts of oxygen diffuse into the gut lumen from the epithelial cells, leading the mucosal microbiome to contain a greater number of aerotolerant species than the lumen. Disruption of the homeostatic release of oxygen by the host, such as during inflammation, leads to a disturbed microbiota, driven by the growth of facultative anaerobes. For readers interested in the other factors that differ along the biogeography of the human gut, we direct them towards reviews that have covered this subject in greater depth.

Current methods for directly sampling the gut are highly invasive, hence most human microbiome studies are limited to the study of faeces. While the faecal microbiome can provide insights into general shifts within the microbiome, it represents only the end-point of a dynamic process occurring along the gastrointestinal tract. Comparison of its profile to that of other gut locations has shown many species which are dominant throughout the gut are not detected within the faeces by sequencing, however may still be present. Ingestible devices are currently under development that facilitate sampling from sites along the gastrointestinal tract, although further development and testing is required before wide-spread application.

In summary, this introduction aimed to provide key information about the diversity and development of the gut microbiome, as understanding the innate complexity of the system is crucial for the interpretation of how microbiome-based interventions can modify microbial communities for the benefit of the host. The various layers of complexity mentioned above (different microbes; strain-level diversity; many unknown ecosystem members; biogeography of the gut) complicate the understanding of interactions between enteric microbes and the host. Nonetheless, progress has been made in all of these aspects of research, facilitating the implementation of microbiome-based applications in health and disease.

METHODS OF MICROBIOME-BASED INTERVENTIONS, THEIR RATIONALES, AND EFFECT ON GUT ECOLOGY

The rationales for microbiome-based interventions are diverse, ranging from the prevention of acute infections to the improvement of life-long health. Depending on the intervention, the mechanism of action by which the microbiome-based intervention works also vary, from restructuring of the entire community, to supplementation of specific molecules that directly affect the host (Fig. 1a). Based on this, the ecological impact of each intervention can be conceptually defined as belonging to at least one of three categories of ecological impacts: species introduction, species depletion, and enhanced growth (Fig. 1b). For example, phage therapy aims to deplete a species within the ecosystem, hence it can be assigned to the ‘species depletion’ category, while prebiotics are selected based on their specific utilisation by a subset of bacteria, hence they belong to the ‘enhanced growth’ category. Grouping microbiome-based interventions into three categories is a simplistic and reductionist approach as many interventions belong to two or three categories and any modification to the gut microbiota is likely to have secondary effects.

The impact of each intervention method on the ecology of the gut microbiome are detailed below, along with mechanistic insight into how they can influence the immune system. Each section, based on a single intervention, have been ordered on the complexity of their interactions with both the resident microbes and immune system. As such, FMT is the most complex, consisting of live microbes, remnant dietary components, phage, and metabolites. On the other end of the spectrum, postbiotics are purified molecules derived from a microbe, which have a direct effect on either the ecosystem or the host, leading to a desired outcome.

Faecal microbiota transplant (FMT)

FMT is the administration of stool preparation obtained from a healthy donor to a diseased patient (recipient) with the goal to treat or alleviate the pathology. Such transplants have been done since the 4th century in China, but the last decade has seen an increase in its clinical application, enhancing our understanding. Modern interest in FMT began with the successful application of FMT to treat Clostridiodes difficile infections. A recent meta-analysis of 45 studies (n = 3768 patients) on the efficacy of FMT to treat C. difficile showed that although highly effective (average success rate between 50.2–96.4%), its success depends on the frequency of transplants, as well as the method of transplantation. The most successful method of transplantation to date is lower gastrointestinal endoscopy (96.4%), with enema being the least effective (50.2%). Repeat administration significantly improved the effectiveness of FMT, independent of the transplantation method.

FMT can lead to community-wide changes in the ecology of the recipient’s microbiome, including the engrafment of species or strains not previously present within the recipient’s microbiome. The effectiveness of FMT to maintain remission in patients with Crohn’s disease is reliant on the engrafment of the donor microbiome. Long-term engrafment of the donor’s microbiome can be difficult to predict as it is dependent on multiple factors including xenobiotics, donor-recipient similarity, and taxonomic profile of the recipient. It has also been suggested that the engrafment of bacteria is not determinative of successful treatment for inflammatory bowel disease (IBD), which may suggest that, in these cases, the non-living elements (e.g. phage and metabolites) are the beneficial elements (see section on faecal filtrate transplants).

Donor-recipient mapping seems to be a key factor in predicting and increasing the success of FMT. The variability in FMT success has been identified to be partly due to the microbiome of the donor; improved success rate is associated with higher richness as well as the relative abundance of specific taxa, such as A. muciniphila and Ruminococcus spp., although such parameters are not universal. It may also be the recipients microbiome which is key, with a depleted recipient microbiome giving the highest chance for engrafment. A lower diversity of eukaryotic viruses
Table 1. Overview of the reasons for microbiome-based interventions.

| Rationale                        | Brief concept                                                                                                                                                                                                 | Examples                                                                                                                                                                                                 |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Prevention of enteric infections | Microbiome-based interventions can help prevent infections via multiple mechanisms. One such mechanism is niche exclusion, which involves commensal species utilising nutrients that the pathogen is specialised into using. Another mechanism is the improvement of barrier functions, which plays a particularly important role in early life. Bacterial production of antagonistic substances such as antimicrobial peptides, or the production of secondary bile acids, have also been shown to be effective in altering susceptibility to infection. | • Reduced epithelial apoptosis during treatment with probiotic strains of *Lactcaseibacillus* spp. (previously *Lactobacillus*) has been proposed as a mechanism for the reduction of necrotising enterocolitis (NEC)\(^{278}\).  
• Colonisation with a closely related strain can lead to competitive exclusion of pathogenic strains. This has been shown for *Klebsiella ooytoca* which prevents colonisation of *K. pneumoniae* colonisation via utilisation of carbohydrates in collaboration with other commensals\(^{56}\). |
| Treatment of infections          | While microbiome-therapies can prevent infection, they can also be utilised to treat infections, either by active depletion of the pathogenic species, or by competing for the niche the pathogen occupies. | • Faecal microbiota transplants (FMT) have been utilised globally for treatment of *Clostridioides difficile* infections\(^{54}\) with a success rate between 80–94% depending on the method used and cohort\(^{106}\).  
• Phage therapy for the treatment of gastrointestinal infections have been highly effective in animal models\(^{259}\), although there have been few clinical trials and those that have been conducted are of limited success\(^{176}\). |
| Gut restoration                  | Repeated antibiotic use or poor diet over long periods of time can lead to the gut remaining in a perturbed state. Replacement of lost or underrepresented species into the ecosystem can provide the opportunity for the gut ecosystem to recover. | • Meta-analysis of 82 studies confirmed that probiotics can reduce antibiotic-associated diarrhea\(^{285}\).  
• FMT has proven effective for improved microbiome recovery from antibiotic treatment\(^{276}\). |
| Prevention of chronic diseases   | Chronic diseases can develop over a long period of time, with multiple factors influencing their chance to occur. By modulating the contribution by gut microbes, we can reduce the chance of chronic diseases developing. | • Long-term (26 years) intake of dietary fibre has been associated with decreased risk of both ulcerative colitis and Crohn's diseases\(^{281}\). Consistent high fibre intake is essential for this association as other studies that show no association between dietary fibre and inflammatory bowel disease (IBD) incidence utilised a single baseline questionnaire to determine dietary intake rather than regular questionnaires\(^{252}\). |
| Disease treatment                | The gut microbiome has been observed to exacerbate certain inflammatory and metabolic conditions. Modification of the microbiome in patients suffering from such conditions may be a route to reduce symptoms and improve patient health. | • The probiotic bacterium, *Hafnia alvei* HA4597, has been shown to reduce feed intake by patients, improving weight loss during dieting\(^{183}\). This was linked to the expression of CtpB, a protein similar to α-melanocyte stimulating hormone, which is involved in the regulation of energy balance\(^{284}\).  
• FMT has been studied for inducing remission in patients with ulcerative colitis\(^{265}\). Success was achieved in combination with pre-treatment using antibiotics\(^{286}\). However, the choice of antibiotics seems important and must be selected with care based on the profiling of antibiotic resistant strains already present within the recipient's microbiome\(^{267}\). |
| Early modulation of the immune system | The early life gut microbiome coincides with mucosal and systemic immune development—and therefore represents an ideal ‘window of opportunity’ for targeted modulation of the gut to direct immune programming. This is particularly important in neonates/infants that have ‘perturbed’ microbial ecosystems, such as preterm babies, those born via C-section or who receive antibiotics. | • Human milk oligosaccharides (HMOs) can be deemed prebiotic\(^{298}\) due to their bifidogenic effect\(^{298}\). *Bifidobacterium* spp. have in turn been shown to be better able to enhance barrier function within the gut when grown on HMOs\(^{269}\). Specific probiotic interventions can substantially affect immune responses early in life. For instance, feeding of *B. infantis* EVC001 was linked to upregulation of IFN\(\gamma\) and silencing of intestinal Th2 and Th17 responses\(^{211}\). |
| Improved nutrition               | Enteric microbes directly interact with both food components and the host. Some foods have been observed to alter the gut ecosystem in a way to improve the nutritional status of the host. This can be done as part of a holistic diet or via targeted intake of specific nutrients. | • Food specifically designed to modify the gut microbiome for the purpose of enhancing host nutritional status have been developed\(^{269}\). The successful application of MDCC-2 to improve growth of undernourished children as well as modification of the gut microbiome confirms the usefulness of such microbiome-targeted approaches\(^{291}\).  
• Variability in glycaemic response to the same diet is linked to a range of microbial functions. Incorporating these variables in a model allowed personally tailored diets to be designed that altered glycaemic response of the individual. The personalised diets had consistent effects on the |
Table 1. continued

| Rationale                      | Brief concept                                                                 | Examples                                                                 |
|--------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Improved vaccine efficacy      | The presence of a microbiome has also been shown to influence vaccine efficiency. This can be due to shared sequence similarity between microbes and the sequences targeted by vaccines, priming the immune system and enhancing the immune-stimulatory effect of these vaccines. Another method is that the microbiota can enhance vaccine response via activation of convergent pathways, leading to a greater response than the vaccine would cause alone. | • The application of probiotic bifidobacteria has been shown to enhance the immune response to a neoeptipe-based cancer vaccine. This was suggested to be caused by the probiotic leading to an increase in taxa with high sequence similarity to the neoepitope, leading to further immune stimulation. • Activation of TLRs by the gut microbiota, specifically flagellated bacteria, significantly increases antibody production against influenza vaccination, in mice. |
| Modulation of drug therapy     | The gut microbiome can modify the ability of an individual to respond to medication. This can occur via direct interaction between the microbes and the drugs, e.g., storage or biochemical modification, or by priming the host to be responsive to antibody therapies. | • Bioaccumulation of common drugs has been shown to be a common feature of commensal gut microbes. This may in turn modify the drug dosage received by a patient, preventing clinical improvement. Microbiome modulation to delete species that impact specific drugs may enhance patient response. |

For each rationale for microbiome-based intervention we provide details about the concept and published examples.

within the recipients’ faeces has also been suggested to be a marker of FMT success, highlighting the need to screen both donors and recipients prior to transplant. Preliminary findings suggested that the donor’s microbiome profile was the main indicator of success, leading to the concept of ‘super donors’, individuals with a highly diverse microbiome that were most effective for FMT. This concept has been criticised due to lacking consistent experimental support, and ignoring other factors, such as metabolite production by the donor’s microbiome.

To circumvent the issue of relying on donors, autologous FMT (aFMT) has been explored. aFMT refers to patients receiving their own stool, biobanked before undergoing treatment, rather than receiving faeces from separate donors. For instance, when using samples obtained after completing a dietary intervention (Mediterranean or green Mediterranean) and then taken regularly over the course of 6 months afterwards, aFMT improved retention of weight loss and glycaemic control conferred by the diet. aFMT has also been shown to be effective in enhancing recovery of a patient’s microbiome after antibiotic treatment. Further experiments have confirmed that aFMT enhances the recovery of both the luminal and mucosal microbiome after antibiotic treatment.

While the majority of FMT trials have focused on adults, its application during early life has also been explored. Children born via CSD have been identified to have a disturbed microbiome during early-life. This altered microbiome has also been linked to reduced immune priming during the first days of life, which may result in the observed increase in occurrence of immune conditions in CSD children in later life. To avoid this, FMT using faecal samples from the mother has been tested. During an initial trial applying FMT to babies to restore a conventional microbiome, the faeces from 29% of mothers were positive for pathogens, highlighting the need for in depth donor screening. Colonisation of a microbiome deprived environment such as the neonatal gut with pathogens may in turn lead to increased incidence of necrotising enterocolitis (NEC) and other infections. An alternative approach to faecal transfers is the transfer of the vaginal microbiome either via a “swabbing” approach or oral administration. Potentially due to this variation in approaches, or due to the vagina being a poor source of gut microbes, results have so far been inconsistent.

Ethical concerns have been raised based on the undefined nature of the material during FMT. This has led to increasing interest in the identification of the key species, consortia of species, or molecules that confer the health benefits.

Faecal filtrate transplant (FFT)

FMT success is generally attributed to the dominant bacterial populations in stool, with a large focus placed on engraftment of donor strains and species. However, the lack of standardisation and use of complex material has been raised as a concern for the wide-spread implementation of FMT. Faecal filtrates aim at removing microbial cells, but retain the viral and small molecules in the donor sample. Faecal filtrate transfer (FFT) was shown to be effective in treating C. difficile which has been proposed to be due to the transfer of bacteriophages. FFT has also been shown to be more effective than FMT when treating NEC in piglets. Comparison of the effectiveness of faecal sediment vs. supernatant for treatment of C. difficile infection has shown a 27% increase in effectiveness when using the supernatant, confirming that active agents other than the bacterial component are important. However, FFT has been tested in few studies that have relied on a small number of patients. Systematic comparisons between FMT and FFT are required using optimised protocols for each approach (application route for FMT and method of filtration for FFT) before solid conclusions can be made. While FFT has been shown to significantly alter the composition of viruses within the gut, the impact on the entire ecosystem is less understood.

**Diet**

There is a large overlap between the chronic diseases linked to diet and those that have been linked to the gut microbiome. These pathologies, such as allergies, obesity (plus metabolic comorbidities), autoimmune, neurological, and oncological disorders, are complex diseases that are to some degree immune mediated with inflammation as a common determinant. Decreased microbial diversity in the gut microbiome is observed both in chronic diseases but also population-wide in Western societies, in which the rates of these diseases are higher. Western diets (WD) are high in processed foods, animal products, and refined grains, and low in whole plant foods such as vegetables, fruits, nuts, and legumes. The impact of a lard-based WD on mice has been shown to be reliant on the presence of a microbiota, as germ-free mice are resistant to obesity from this diet. This interaction between WDs and the microbiota has been confirmed by microbiota transfer experiments into germ-
free mice\textsuperscript{96}. These showed that microbiota of obese mice significantly increased body-fat gained compared to transfer of a lean mouses microbiota\textsuperscript{97}.

Different food components and dietary patterns shape the gut microbiome with associated immune modulating effects. Whole plant foods (fruits, vegetables, wholegrains, legumes, and nuts) are the main source of naturally occurring dietary fibres (see section on prebiotics\textsuperscript{92}). Fermentable dietary fibres are converted into metabolites such as SCFAs which are important mediators for the interaction between the gut microbiome and immune system\textsuperscript{98} and affect the balance between pro- and anti-inflammatory mechanisms. For example, the SCFA butyrate increased the generation of extrathymic $T_{reg}$ cells in mice, additionally, periphery de novo $T_{reg}$ cell generation can be stimulated by the SCFA propionate\textsuperscript{99}. Fibre-rich diets also promote a mature intestinal mucus layer and barrier, decreasing pathogen infection and risk of colitis\textsuperscript{100}. In contrast, fibre deficient diets are low in available nutrients for the gut microbiome and can promote microbial degradation of mucus, which contributes to the erosion of the colonic mucus barrier, increasing pathogen susceptibility\textsuperscript{100}.

The refined food components of processed foods, which dominate WDs, are easily fermented in the small intestine to promote bacterial overgrowth and an undesirable microbial composition and metabolic profile that may negatively influence immune functions\textsuperscript{101} while not being available to colonic microbes\textsuperscript{102}. Additionally, the high fat content of WDs may promote the growth of the pathobiont \textit{Bilophila wadsworthia} which has been associated with inflammation, intestinal barrier dysfunction, glucose dysmetabolism and hepatic steatosis in mice\textsuperscript{103}. Emulsifiers present in processed foods such as carboxymethylcellulose have been shown to alter gut microbiota and enhance chronic intestinal inflammation in mice by inducing the expression of gene clusters mediating Crohn’s disease- associated adherent-invasive \textit{E.coli}\textsuperscript{104}. The combined effects WDs negatively influence the composition of the gut microbiome and may weaken mucosal barriers to promote an inflammatory response.
Fruits and vegetables contain a variety of fibres with varying physicochemical properties. Human intervention studies have noted an inhibitory role of fruit and vegetables intake against the growth of pathogenic clostria (Clostridium histolyticum/perfringens) among other positive effects on the microbiome. Whole grains contain a diverse array of hemicellulose fibres, such as xylans and β-glucans, in addition to cellulose, resistant starches, and oligosaccharides. Increasing consumption of wholegrains (whole-grain-barely and/or brown rice) to 60 g/day has been shown to increase microbial diversity and reduce both, plasma interleukin-6 (IL-6) ratio and peak postprandial glucose. The response to increased whole-grain consumption may be highly individualised. Improvements in glucose metabolism in response to consuming a high fibre barley-kernel bread (over 3-days) was associated with an increase in Prevotella in responders (who had a higher ratio of Prevotella/Bacteroides).

Dietary patterns such as the Mediterranean diet (MD) combine many universally accepted food-based dietary guidelines and are recommended for their health promoting properties. The MD is characterised by a high intake of plant-based foods, moderate intakes of olive oil, fish and poultry, and low intakes of dairy products, and red meat. This dietary pattern is inversely associated with a reduced risk of cancer and cardiovascular disease. A meta-analysis of 165 RNA amplicon data (1931 human faecal samples) noted that the gut microbiome associated with the MD was enriched in bacteria with potential anti-inflammatory properties (e.g. Akkermansia Vs. Fusobacterium). Additionally, high level of adherence to a MD was associated with an increase in faecal SCFAs whilst low levels of adherence were associated with higher urinary trimethylamine oxide levels (linked to atherosclerosis and cardiovascular disease). Due to individual variability and low adherence to prescribed diets, altering their impact, strategies are needed to maintain the impact of diets while being tailored to increase individual adherence.

Ketogenic diets (KDs), restrict carbohydrate intake and provide high levels of fat and adequate protein. KDs have been associated with a reduced incidence of seizures in children with therapy resistant epilepsy the effects of which may be mediated by the gut microbiome (via bacterial cross-feeding and increases in Akkermansia and Parabacteroides) through their modulation of hippocampal GABA/glutamate ratios. The restriction of carbohydrate intake, has been shown to be beneficial to patients with non-alcoholic fatty liver disease (NAFLD). Over 14 days on this diet, community-wide shifts causing significant decrease in SCFA production, but increase in folate production which was associated with decreased liver fat. When compared to restriction of fat intake, patients undergoing carbohydrate restriction for 24 weeks lost significantly more weight. However, compositional shifts observed on KDs may have a less positive influence on gut and overall health, noted by decreases in health promoting (and fibre fermenting) bacteria such as bifidobacteria and Eubacterium rectale and their metabolites. Though evidence highlights short-term beneficial effects of KDs in certain populations, its restriction of fermentable fibre and high fat content may detrimentally impact the gut microbiome and immune response in the long term.

Personalised nutrition focuses on the use of person-specific factors (genetic, phenotypic, medical, nutritional or other relevant information) to develop nutritional recommendations tailored for each individual with the goal to preserve, or increase health. Given the pronounced inter-individual variation of the gut microbiome, the microbiome could constitute a key determinant of personalised nutrition. By identifying key microbe features that predict the response to particular food components personalised nutrition can inform the design of a diet offering favourable health outcomes.

For example, there is emerging evidence that an individual’s microbial composition may influence their ability to lose weight when following specific diets. Stratifying individual’s according to their microbial community may help predict their responses to certain diets. Individuals with a gut microbiome dominated by Prevotella may achieve optimal weight loss by adhering to a high fibre diet, which is not observed among individuals with a gut microbiome dominated by Bacteroides. The value of a personalized use of diet informed through microbiome information is also supported by the Prevotella-dependent effects of barley-kernel bread on glucose discussed above. However, increasing bifidobacteria in individuals with a gut microbiome dominated by Bacteroides has been shown to improve metabolic parameters which could be used as a weight loss strategy. Although the concept of personalised nutritional advice incorporating microbiome analysis is promising, this area of research is still in its early stages with noteworthy limitations including cost and a lack of causal data from clinical trials underpinning recommendations.

Fermented food

The International Scientific Association for Probiotics and Prebiotics (ISAPP) has defined fermented foods and beverages as “foods made through desirable microbial growth and enzymatic conversions of food components”. Fermented foods in which live organisms are present include yoghurt, sour cream, kefir, most cheeses, sauerkraut, kimchi, miso, natto, kombucha, some beers, and non-heat-treated (raw) fermented sausages (e.g. salami). If served uncooked, fermented foods often contain a high number of live microbes and have a long history of safe consumption. Lactic acid bacteria (LAB) are essential in the production of fermented foods and large quantities of live LAB may be consumed via fermented foods e.g., yoghurt and cheeses. A large-scale genome-wide analysis (analysing 9445 metagenomes from human faecal samples) noted that the occurrence of LAB species was typically low and associated with age, lifestyle, and geographical location. However, it was noted that similar LAB strains occur in both food and gut microbiomes indicating that fermented foods may be the direct source of LAB found in the microbiome. It is important to consider that although live microbes from fermented foods reach the gut microbiome alive, they are not adapted to the gut and thus unlikely to persist and have a major effect on the overall microbial community. Due to this, it is likely that the metabolites produced by these species, which are found in high concentrations within the fermented foods, are the active agents which confer any beneficial effect.

Although the microbes present in fermented foods are unlikely to exert a major impact on the gut microbiome structure, evidence is emerging that they can influence the host and its immune system. In a 17-week randomised prospective study (n = 18) during which participants increased their baseline average intake of fermented foods from 0.4 ± 0.6 to 6.3 ± 2.9 servings per day, it was found that a diet high in fermented foods steadily increased gut microbiome diversity and decreased inflammatory markers in the blood. Yoghurt consumption has been associated with a higher relative abundance of species used as yoghurt starters (Streptococcus thermophilus and Bifidobacterium animalis subsp. lactis) in participants who also showed improved metabolic health characterised by reduced visceral fat. Yoghurt contains concentrated milk fermentation metabolites such as branched chain hydroxy acids (BCHA). Recent studies in mice have noted that feeding the equivalent of 2 servings per day of yoghurt prevented insulin resistance and hepatic steatosis in diet-induced obesity. This was partly driven by changes in gut microbiome composition and maintaining BCHA levels which are typically reduced in diet-induced obesity.

Although there is limited and conflicting evidence that fermented foods contribute to the repopulation and densification of the gut microbiome, they are culturally acceptable and safe vehicles by
which live microorganisms can temporarily reside and pass through the human alimentary canal, influencing the immune system. Such foods they may confer health benefits attributed to their low pH and unique preparation methods which expose individuals to microbial species not otherwise present in the food chain.

**Prebiotics**

A prebiotic is currently defined as a substrate that is selectively utilised by host microorganisms conferring a health benefit. Although current definitions of prebiotics have been criticised for not allowing a clear distinction between dietary fibres that are prebiotic and those that are not, non-digestible carbohydrates (NDCs) can be used to modulate both composition and function of the gut microbiome.

The administration of fibre supplements, no matter if they are considered traditional prebiotics or not, result in specific changes in the gut microbiome. These changes are fibre-type specific, meaning, different fibres enrich for different bacterial types. Several studies have established dose-response relationships between the administration of NDCs and compositional shifts. At higher doses (10–30 g), the magnitude of the effects of NDCs can be significant, enriching some species by several thousand percent to reach relative proportions of >20% of the gut microbiome. Using a dose-response trial with three type-IV resistant starches, crystalline and phosphate cross-linked starch structures were shown to induce divergent and highly specific effects on microbiome composition that are linked to directed shifts in the output of either propionate or butyrate. These findings support the concept of precise gut microbiome composition modification through discrete fibre chemical structures. However, these responses are for the most part individualised and reversible when the host is no longer receiving the substrate.

Ecology can be used to explain the effect of dietary fibres and prebiotics. Fibres provide substrates (resources) that select for microbes that are the most adapted to utilising these fibres under the competitive conditions present. The colon consists of a complex ecosystem of microbes in which primary degraders, secondary degraders, and cross-feeders are capable of growing on nondigestible fermentable carbohydrates (NDFCs) and utilising its by-products. Varying microbial species are required to degrade specific fibre types and certain bacteria are highly specialised and significantly contribute to fibre degradation, often referred to as keystone species. Intervention trials with resistant starch, a microbiome-accessible NDF, noted significant increases in Ruminococcus bromii and E. rectale with supplementation. R. bromii utilisation of NDFCs can benefit other microbial species by releasing sugars and acetate and can therefore be considered a keystone species. Interestingly, the more complex fibre structures become, the more specific the response. For example, while the effects of high molecular arabinoxylan is highly specific to the species B. longum and Prevotella copri, yet arabinoxylan oligosaccharides seem to lower specificity and promote multiple species of Bifidobacterium and Prevotella, as well as several additional genera (e.g., Eubacterium and Roseburia). Specificity is not only determined by the ability of bacteria to utilise the fibre but also by selective colonisation (attachment) to the substrate.

In addition to impacting the composition of the microbiome, fibre supplements can influence the production of microbial-derived metabolites that influence immune responses (see section on diet). SCFA production is dependent on the fibre type and species present in the host microbiome, providing a framework for directing SCFA production by utilising different fibres for a recent review see Vinelli et al. (2016).

Despite the many potential positive effects of fibre supplementation, rodent studies have indicated that high-dose supplementation with certain soluble fibres (such as inulin and pectin) can induce cholestasis, hepatic inflammation and icteric hepatocellular carcinoma (HCC) in mice. Singh and colleagues suggested that the production of excessive amounts of butyrate (beyond levels tolerable to the host) in combination with changes to the microbiota caused by a high fat diet, and inflammation may accelerate tumour formation. In addition, fermentable fibres have been shown to exacerbate severity of DSS-induced colitis in mice. These findings show potential detrimental impact when using certain soluble fibres as supplements in high doses.

The capacity to identify the mechanisms by which specific fibre types regulate host microbial populations and metabolism may offer the possibility for targeted therapeutic dietary fibre interventions to regulate disease states associated with altered metabolism and inflammation. However, well controlled human clinical trials that establish the effects of fibre supplements or prebiotics on the gut microbiome and host health parameters are scarce and effects are highly inconsistent.

**Probiotics**

Probiotics are live microorganisms, and thus directly add to the diversity of the native gut ecosystem. The most recent definition of a probiotic is “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.” This definition is purposely broad and inclusive, but the difficulties lie in the demonstration of a health benefit. Probiotics come in a range of complexities, from single strains to complex microbial assemblages of multiple strains from different species that are either administered in foods or as supplements.

Traditionally, probiotics have consisted of single strains which may or may not have been isolated from the environment they are applied to. One of the most studied probiotic strains is Lactobacillus rhamnosus GG (LLG). LGG has been used to treat C. difficile colitis in humans and has been shown to restore leptin responsiveness in mice fed a high-fat diet, suggesting it may improve weight loss. When given to mice fed a high-fat diet, LGG was observed to decrease the proportion of Pseudomonadota (formerly Proteobacteria), without impacting overall microbiome diversity. Until recently, probiotics have been limited to a few known taxa (mainly lactobacilli and bifidobacteria), for which multiple strains have been identified and characterised.

Increased activity in cultivating previously unknown taxa from the human gut has provided access to a wider array of strains that may be used as probiotics. Advances in sequencing technology have also facilitated greater insight into the association of these species and strains with health conditions. By utilising the results from sequencing to identify which strains may be beneficial for specific conditions, we can generate probiotics which were not possible before. Probiotics selected via this format have been termed ‘next generation probiotics’ (NGPs). Due to these strains being selected to treat or prevent specific diseases or conditions, they are likely to fall under the broader category of ‘live biotherapeutic products’ (LBPs) (discussed in Box 1), which would impose a more stringent regulatory framework than those required to be deemed safe as a food supplement and given ‘generally considered as safe’ (GRAS) status. One of the most studied NGPs is A. muciniphila, of which one strain (Muc) has been approved, in pasteurised form, as a food supplement and categorised as a novel food by the European Food Safety Authority (EFSA). Ingestion of either live or pasteurized A. muciniphila have been shown, both in human and mouse trials, not to cause community wide changes in the microbiome while improving host metabolic parameters including insulin sensitivity and plasma cholesterol levels. In addition to A. muciniphila, strains of Faecalibacterium prausnitzii and Bacteroides fragilis have also been studied as potential NGPs, although human trials have not yet been reported. So far, human studies failed to show a significant effect of probiotics on the gut microbiota. This may be in part due to many of these NGP
Bacteriophages (or phage) are viruses that target bacteria. Most phage therapy is achieved through the use of multi-strain consortia rather than the traditional single strain approach. The production of novel intestinal microorganisms without GRAS status to treat disease has prompted the FDA to define a new regulatory category called ‘live biotherapeutic products’ (LBPs) that fall into the broad definition of probiotics, but are used to treat health conditions. This new category of LBPs are regulated as a drug and are hence subject to the stringent regulations in terms of safety, clinical efficacy, and current good manufacturing practices.

The production of novel single strain probiotics that are classified as LBPs can directly benefit from the experience of producing probiotics at scale, though many strict anaerobic gut bacteria are more fastidious than lactobacilli or bifidobacteria. This requires extra investment to optimise growth conditions during production—even more so for the intestinal microbes that depend on close interactions with other microorganisms for optimal growth.

The production of multi-strain consortia, however, poses additional biotechnological challenges. Optimal growth conditions will vary between strains during the overall process. When produced as individual mono-cultures that are subsequently mixed in a final product, production complexity scales linearly with the number of strains.

Alternatively, multi-strain consortia can be directly produced as cocultures. While this addresses the complexity problem of scaling, determining growth conditions that apply to all strains simultaneously is far from trivial. Furthermore, because each strain will typically have different growth rates, guaranteeing reproducibility and consistency of the final product is hard. These challenges can be overcome by incorporating ecological interactions into consortium design.

The challenge of multi-strain consortium LBPs expands beyond the production process into clinical application, where consistent activity is a requirement for regulators. The control over pharmacokinetics and pharmacodynamics, i.e. growth and exertion of the desired activity of this new modality is currently the biggest challenge that remains to be shown in humans and will be the make or break of the efforts to mimic FMT in a standardised fashion using defined bacterial consortia.

The abundance of phage within the gut has also been linked to the severity of inflammation caused by IFN-γ activation through a TLR9-dependent pathway. Stimulation of IFN-γ production from dendritic cells incubated with phage DNA, but not empty phage capsids, confirms that phage DNA is immunostimulatory. The immunogenicity of phage proteins is likely specific to each phage due to the diversity of phage that exist. For example, the T4 phage contains multiple capsid proteins that stimulate an immune response in humans, although safety testing of T4 has confirmed it causes no adverse effect after oral treatment.

Phage cocktails to treat strains of 

C. difficile infections, which have, in fermenter experiments, been shown to eliminate 

C. difficile, while also avoiding major impact to the commensal groups (bifidobacteria, enterococci, enterobacteria, and lactobacilli). Phage isolated against disease-associated bacteria, such as Adherent invasive Escherichia coli (AIEC), have also been applied to reduce the severity of inflammation in DSS treated mice. Another species targeted to reduce inflammation is Klebsiella pneumoniae. A consortium of five phage that target K. pneumoniae has been developed and shown to reduce the severity of DSS induced inflammation, and an initial human study has shown this consortium is safe for human use, and viable.

However, the interdependency between gut microbes due to cross-species interactions mediated by metabolite production/utilisation can nonetheless lead to collateral effects. Phage treatment against E. coli and Clostridium sporogenes has been observed to have knock-on effects on non-target species, reducing the abundance of B. fragilis, while significantly enhancing the abundance of Phocaeicola vulgaris. This in turn modified the metabolome of the gut, which can affect the bioavailability of molecules to the host. While this was observed in mice colonised with a minimal microbial consortium, the impact to a complex community is likely lesser.

The specific nature of phage is also proposed to be a limitation to the application of phage therapy to treat gastrointestinal infections as the phage maintained in culture in laboratories may no-longer be able to replicate in the native pathogenic strains. Phage resistance has also been observed to occur within gut bacterial species, leading to a coexistence between phage and their host, rather than depletion of the latter. Due to their narrow host range and potential coexistence, the ability of phages to modulate the gut microbiome is thought to be limited.

The abundance of phage within the gut has also been linked to increased inflammation caused by IFN-γ activation through a TLR9-dependent pathway. Stimulation of IFN-γ production from dendritic cells incubated with phage DNA, but not empty phage capsids, confirms that phage DNA is immunostimulatory. The immunogenicity of phage proteins is likely specific to each phage due to the diversity of phage that exist. For example, the T4 phage contains multiple capsid proteins that stimulate an immune response in humans, although safety testing of T4 has confirmed it causes no adverse effect after oral treatment.

While thousands of phage have been identified to exist within the gut, few have been isolated directly from this environment and fewer still have had their impact on the community studied. Further research is required in this area to understand the direct and indirect impact of phage therapy on both the microbial community and the host.

Postbiotics

Postbiotics are functionally bioactive molecules produced by microbes, formally defined as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. It is key within this definition that while intact microbial cells may be deemed a prebiotic, the preparation is not alive or viable. This prevents the chance for colonisation and means health benefits conferred by postbiotics are reliant on regular intake to maintain the presence of the bioactive molecules.

An example of an intact cellular postbiotic is the preparation of pasteurised A. muciniphila cells. A trial comparing pasteurised A. muciniphila cells to a living culture showed that the pasteurised cells, but not the living cells, improved insulin sensitivity and reduced plasma cholesterol levels. The active molecule responsible for the beneficial effects of pasteurised A. muciniphila cells has been identified to be a membrane protein, Amuc_1100.

p40 is another protein which has been identified to be the element conferring the beneficial effects of the common probiotic, LGGs, as it secretes p40 into the environment. While this protein is

Box 1. Biotechnological trials and tribulations of microbiome therapies

- Traditional probiotics, i.e. lactate producing bacteria, which have been ‘generally considered as safe’ (GRAS) by the US Food and Drug Administration (FDA) and European Food Safety Agency (EFSA), have been broadly used as food supplements. The promise of novel intestinal microorganisms without GRAS status to treat disease has prompted the FDA to define a new regulatory category called ‘live biotherapeutic products’ (LBPs) that fall into the broad definition of probiotics, but are used to treat health conditions. This new category of LBPs are regulated as a drug and are hence subject to the stringent regulations in terms of safety, clinical efficacy, and current good manufacturing practices.
- The production of novel single strain probiotics that are classified as LBPs can directly benefit from the experience of producing probiotics at scale, though many strict anaerobic gut bacteria are more fastidious than lactobacilli or bifidobacteria. This requires extra investment to optimise growth conditions during production—even more so for the intestinal microbes that depend on close interactions with other microorganisms for optimal growth.
- The production of multi-strain consortia, however, poses additional biotechnological challenges. Optimal growth conditions will vary between strains during the overall process. When produced as individual mono-cultures that are subsequently mixed in a final product, production complexity scales linearly with the number of strains.
- Alternatively, multi-strain consortia can be directly produced as cocultures. While this addresses the complexity problem of scaling, determining growth conditions that apply to all strains simultaneously is far from trivial. Furthermore, because each strain will typically have different growth rates, guaranteeing reproducibility and consistency of the final product is hard. These challenges can be overcome by incorporating ecological interactions into consortium design.
- The challenge of multi-strain consortium LBPs expands beyond the production process into clinical application, where consistent activity is a requirement for regulators. The control over pharmacokinetics and pharmacodynamics, i.e. growth and exertion of the desired activity of this new modality is currently the biggest challenge that remains to be shown in humans and will be the make or break of the efforts to mimic FMT in a standardised fashion using defined bacterial consortia.
discussed in greater detail in the next section, in brief it has been shown to improve barrier function184. It is possible that this protein influences the ecology of the gut, as administration of LGG significantly increased the richness and evenness of the microbiome when administered during the first week of life185. Direct supplementation of SCFAs as probiotics for improving mucosal development has been investigated since the 1950s186. As important microbial metabolic molecules, it is not surprising that supplementation of SCFAs can alter the gut microbiome. Butyrate supplementation (300 mg/Kg daily) increased the relative abundance of multiple genera in mice, including *Bacteroides* and *Rikenellaceae KX*187. In humans, 4 g daily butyrate supplementation for a month across 30 individuals was observed to cause a community wide shift, led by *Lachnospiraceae*, including *Dorea formigenan-*188. Similarly, propionate supplementation (1% within drinking water) reduced the impact of high-fat diet in mice, recovering the microbiome richness to control levels and promoting the occurrence of *Bacteroides* and reducing that of *Lactobacillus*189. Secondary bile acids (SBAs) represent another main category of microbial molecules proposed for use as probiotics, created by modification of primary bile acids released by the host into the gut lumen. The gut microbiome therefore acts as a key modulator of the bile acid pool, which directly regulates certain intestinal metabolic molecules proposed for use as postbiotics, created by human host, and has been shown to reduce in abundance of multiple genera in mice, including *Bacteroides* in mice 199. However, relative abundance of *Bacteroides* and decreases *Bacteroides* in mice199. However, these findings are in contrast to observations of increased SBA-producing genes in the gut of patients with colorectal cancer200. The detrimental impact of SBAs is supported by studies in mice showing that DCA can induce colonic tumour formation201.

Currently only a few microbial metabolites and proteins have had their therapeutic potential studied, yet the gut microbiome produces thousands of metabolites and proteins202–204 with more discovered each year205. Detailed description of the molecular effector landscape of the gut microbiome will be a major endeavour for coming years. For those molecules that have been studied, standardisation of dosages will facilitate greater understanding of their impact on the ecology of the microbiome as current variation in treatment between studies prevents direct comparison of results.

**IMMUNE MODULATION BY MICROBIOME-BASED INTERVENTIONS**

In this section, we detail some of the known effects of microbiome-based interventions on the immune system. As this is a broad field of research, we have focused this section on interactions for which mechanisms have been studied and those with therapeutic application. Each subsection focuses on a mechanism by which microbial effectors (e.g., FMT) impact immune targets (e.g., cytokine production). Many studies which identify an association between a change in the microbiome, such as one caused by a microbiome-based intervention, and a change in host phenotype fail to provide a mechanisms204. Due to the difficulty of conducting mechanistic experiments in humans, we also consider mouse and cell lines experiments to provide greater insights into the pathways and cells involved. However, mechanisms identified in mouse experiments may not transfer to humans, hence their validation is still required in humans205. An overview of the discussed mechanisms is shown in Fig. 2.

**Modulation of early-life priming of the immune system**

Establishment of the gut microbiome in early life overlaps with the immune priming window. Epidemiological and more recent mechanistic studies indicate that a perturbed perinatal gut microbiome is associated with heightened risk of developing immune-mediated disorders, including atopic dermatitis, asthma, food allergies, chronic intestinal diseases, and autoimmune conditions206,207.

Immune priming begins in utero with the mother and can be linked to increased *Bifidobacterium* over the course of pregnancy. Supplementation of germ-free dams with *Bifidobacterium breve UCC2003* is associated with transcriptional and morphological changes in the placenta and foetal compartments, including alterations of foetal liver immune pathways208. Other studies in humans have also indicated that maternal diet, such as fibre, and microbiome shape immune factors in cord blood, being associated with cord blood IgA209.

As discussed above, there is a strong evolutionary link between diet, especially human milk, the gut microbiome, and infant health. Components of human milk are known to beneficially drive immune programming and maturation (for a recent review see Singh et al.210). Several recent studies have suggested a number of mechanisms by which human milk-*Bifidobacterium* interactions directly influence early life immune responses. A lack of *Bifidobacterium* and associated HMO-metabolism genes is associated with a heightened inflammatory state in infants, including higher levels of neutrophils and basophils (and plasma TNF-α and IL-17A), while infants with higher endogenous *Bifidobacterium* were observed to have had a higher frequency of anti-inflammatory monocytes and regulatory T cells, and elevated levels of circulating IL-10. Direct supplementation with *B. longum* subsp. *infantis* EVC001, which encodes a range of HMO metabolism genes, was associated with modulation of intestinal T cell responses; Th2 and Th1-associated cytokines were reduced to undetectable limits, whilst interferon β (IFNβ) increased in faeces. Moreover, supplemented infants had higher levels of a key metabolite, indole-3-lactic acid (ILA), which exerted direct regulatory effects on Th2 and Th17 cells in vitro, via the induction of regulatory galectin-1, which is known to limit T cell activation (Fig. 2)211. Linking to ILA, microbial-derived components and metabolites signal via the aryl hydrocarbon receptor (AhR), a transcriptional factor that regulates the host immune system212. Endogenous ligands of AhR are contained in foods such as brassicas and are converted into AhR ligands such as indole and indole derivatives by the gut microbiome. During early life, certain *Bifidobacterium* species in the infant gut can metabolise human milk derived components, i.e., aromatic amino acids (tryptophan, phenylalanine and tyrosine), into their respective aromatic lactic acids (ILA, phenyllactic acid and 4-hydroxyphenyllactic acid) via aromatic lactate dehydrogenases. ILA from *Bifidobacterium* activates AhR in a dose-dependent manner in vitro, and modulated CD4 + T cells and monocytes responses ex vivo213. These studies have begun to shed light on how key microbial-derived
metabolites modulate developing immune responses in early life, and may provide a key link as to why formula-fed infants (that have reduced levels of *Bifidobacterium*, and HMOs) are, in some cases, at a heightened risk of later life immune-mediated conditions like asthma given their potentially skewed initial immune priming.

Strengthening of the epithelium barrier during early life is critical to limit unregulated stimulation of the mucosal and systemic immune system that may lead to inflammatory associated conditions. A particular condition of concern during early life is NEC, which impacts between 5–15% of preterm infants. Previous studies in mice have indicated that *Bifidobacterium* plays an oversized role in guiding epithelial barrier development. Specifically, supplementation with *B. breve* UCC203 during the neonatal window was associated with whole scale transcriptional responses in the small intestinal epithelial compartment, with stem cell marker genes being selectively targeted, indicating an increased regenerative potential of the epithelial layer (Fig. 2). This is important in the context of NEC, as numerous studies have shown that supplementation with *Bifidobacterium* (and *Lactobacillus*) probiotics significantly reduces NEC incidence in preterm infants, including strain EVC001. Acetate is not the only SCFA to influence barrier function; butyrate has been shown to improve barrier integrity, but increase permeability at high doses. When administered to mice at 5% of total food weight, given *ad libitum*, butyrate significantly increased colonic expression of occludin, claudin-5, and zonula occludens protein-1 (ZO-1), leading to a significant decrease in intestinal permeability. When administered to mice at 5% of total food weight, given *ad libitum*, butyrate significantly increased colonic expression of occludin, claudin-5, and zonula occludens protein-1 (ZO-1), leading to a significant decrease in intestinal permeability. When administered to mice at 5% of total food weight, given *ad libitum*, butyrate significantly increased colonic expression of occludin, claudin-5, and zonula occludens protein-1 (ZO-1), leading to a significant decrease in intestinal permeability.

The probiotic strain LGG secretes two small soluble proteins, named p75 and p40, both of which inhibit cytokine-induced apoptosis in cultured epithelial cells. By activating the epidermal growth factor receptor (EGFR), and its downstream target, Akt, p40 has been identified to prevent apoptosis and maintain barrier integrity in mice. This provides a mechanism by which LGG improves intestinal development and tight-junction formation during the first week of life in mice. The protein, Amuc_1100, from *A. muciniphila* Muc, has also been shown to improve barrier function when applied to CaCo2 cells via interacting with toll-like receptor 2 (TLR2). Cell line

**Modulation of innate immune function**

As discussed in the previous section, enhancing barrier function in early life is a key mechanism by which probiotics can help reduce the incidence of NEC, but barrier function is also important in adults. The term ‘leaky gut’ has been used to describe when reduced epithelial barrier function leads to increased occurrence of microbial products within the body. Both probiotics and prebiotics have previously been found to improve barrier function in patients with obesity.

Intestinal permeability is also impacted by SCFAs. In experiments using CaCo-2 cells, *Bifidobacterium bifidum* was shown to reduce the impact of TNF-α induced barrier permeability via production of acetate. In mice, reduced barrier permeability cause by oral acetate supplementation (300 mM in the drinking water beginning two days prior to the experiment and continuing for the duration) reduced susceptibility to DSS colitis. Acetate is not the only SCFA to influence barrier function; butyrate has been shown to improve barrier integrity, but increase permeability at high doses. When administered to mice at 5% of total food weight, given *ad libitum*, butyrate significantly increased colonic expression of occludin, claudin-5, and zonula occludens protein-1 (ZO-1), leading to a significant decrease in intestinal permeability. Cell line experiments have shown that butyrate also upregulates expression of IL-10 receptor α subunit, a molecule shown to be essential for barrier formation.

**List of Mediators:**

- Indole-3-lactic acid
- Amuc_1100
- p40
- Butyrate
- Propionate
- Secondary bile acids
- Protease
- Human milk oligosaccharides
- TLR2
- EGFR
- Tight junctions
- Primary bile acids

**Fig. 2** Visualisation of some discussed mechanisms of how microbiome-based interventions can modulate the immune system. Each interaction is numbered based on the sub-section they are detailed in. The key mediators and molecules involved are detailed below the scheme. Species known to conduct these interactions are given as examples in black. The mucus layer is depicted in green. As a schematic, the sizes and location of mediators and microbes have been modified to enhance visualisation.
experiments have also shown that activation of TLR2 can increase the expression of tight junction proteins, which may be the mechanism by which *A. muciniphila* improves barrier function (Fig. 2). In human trials, *A. muciniphila* Muc can improve barrier function, as shown by reduced plasma LPS levels, however, this effect was only significant when pasteurised cells and not live cells were ingested.

Before microbes can reach the intestinal epithelium, they must pass the mucus layer which forms a physical barrier between the microbes and the host. Decreased secretion of structural components of the mucus layer, such as MUC2, has been associated with the development of inflammatory conditions within humans. The mucin layer can be enhanced in different ways. Butyrate has been shown to increase MUC gene expression when applied directly to goblet cells (Fig. 2). In mice, increased release of mucin after administration of butyrate causes the mucus-associated microbiome to expand and reduces the impact of infection-induced inflammation. Exposure of mice to bacterial products such as LPS and peptidoglycan enhances mucin production and recovery of the mucin layer after inflammatory intervention, although this is likely to be dependent on the species present. For example, *A. muciniphila* is known to degrade mucin but it also increases the number of goblet cells within the ileum of treated mice. It has been suggested that *A. muciniphila* enhances expression of the Wnt/B-catenin pathway, increasing intestinal epithelial cell proliferation, however this has only been shown in chickens. Butyrate has also been shown to enhance MUC2 expression in mice, leading to increased mucin production and an associated increase in *A. muciniphila*. While *A. muciniphila* is one of the best studied mucin-associated bacteria, *Bifidobacterium* spp. have been shown to enhance goblet cell activity in mice, reportedly via production and secretion of acetate. Stimulation of mucin production is not limited to bacteria either; the phlEG37k phage has also been shown to stimulate MUC2 expression, reducing the severity of gastrointestinal inflammation in treated mice.

Mononuclear phagocytes, macrophages and dendritic cells (DCs), within the gastrointestinal tract have also been observed to be modulated by microbiota-based interventions. Butyrate can stimulate differentiation of monocytes to macrophages via inhibition of histone deacetylase 3 (HDAC3) and alter activity by increasing antimicrobial peptide production via reducing activity of mTOR kinase. This was confirmed in vivo by giving mice butyrate in their drinking water (150 mM for seven days), after which their colonic macrophages had higher antimicrobial activity than those given a saline solution. In vitro experiments have also shown that conditioned media from probiotic strains, such as LGG, can enhance the rate at which macrophages kill ingested bacteria. This is done via increasing reactive oxygen species (ROS) generation by enhancing the expression of NADPH oxidase. Some LAB strains have been shown to modify the activity of DCs via the induction of tolerogenic properties. When bone marrow-derived dendritic cells, treated with the probiotic strain *L. rhamnosus* LR-32 were transferred into mice, they conferred a protective phenotype on the recipients to 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis due to the higher abundance of tolerogenic DCs. LAB strains found in fermented foods, particularly sauerkraut, produce D-phenyllactic acid, leading to increased serum levels, which is recognised by the HCA3 receptor on monocytes, altering their migration.

**Modulation of T cell populations**

In addition to modulation of innate immunity, microbiome-based interventions can have profound effects on the adaptive immune system. For example, in patients with end-stage renal disease, daily intake of propionate (1000 mg) was shown to expand the Treg population within the peripheral blood and has consistently been shown to decrease the levels of C-reactive protein, a marker of inflammation, in peripheral blood by half, although its influence on other inflammation markers (IL-2, IL-17) are inconsistent. Propionate has also been shown to modulate the activity of immune cells, including increased production of IL-10 by Tregs, which leads to inhibition of Th17 cells (Fig. 2). In the context of Multiple sclerotic, patients receiving propionate daily (1000 mg) for 14 days reported alleviation of clinical symptoms and a reduced risk of disease progression if taken continuously over a year.

Modification of bile acids by the gut microbiome produces a wide range of SBAs, many of which impact the immune system and some of which have been applied therapeutically. The SBA lithocholic acid (LCA) is a potent inhibitor of IL-1β production in macrophages via inhibiting activation of the NLRP3 inflammasome. Dominant human gut bacteria, including *Gordonibacter pamelaeae*, *Eggerthella lenta*, and *B. fragilis*, were identified to modify LCA into 3-oxolithocholic acid (3-oxoLCA) and isolithocholic acid (isola) in a concentration-dependent manner. Both of these metabolites reduced the differentiation of Th17 cells but had no impact on Treg or Th1 cells in human cell lines and mouse models. However, LCA itself has been shown to inhibit differentiation and activation of Th1 cells (Fig. 2). Taken together, these results suggest that bacterial modification of bile acids, particularly the production of LCA and its derivatives, have a substantial impact on T cell populations and their activity.

Some microbial metabolites have been identified to act as AhR ligands, detailed above, and modulate the T cell population of the gut. Metabolism of tryptophan, by the gut microbiome produces indole-3-acetic acid (IAA), leading to activation of AhR via IL-22 production, improving intestinal recovery in colitis mouse models. IAA-induced IL-22 production is key for colonisation resistance to gastrointestinal fungal infections in mice. While postbiotic treatment with IAA has not been studied in humans, many lactobacilli used as probiotics are IAA producers. Many other immune cells, other than T cells which have been the focus of this section, are impacted by the gut microbiome. As such, they can be part of the mechanism by which microbiome-based interventions impact the immune system. Recently, probiotic bacterial consortia have been developed to modulate immune populations. GUT-108 is one such consortia which reduces the CD4 + T cell population within the gut, reducing the abundance of multiple inflammatory cytokines. While effective in mice, clinical trials are required to confirm its application in humans and better understand the mechanisms by which it affects the immune system.

**Modulation of cytokine levels**

Cytokines are host molecules used for communication between immune cells. Altering the abundance of these molecules can change the migration and activity of specific immune cell types. Gut microbes have evolved multiple methods to modulate the ability of cells to produce and secrete these molecules. Lactoceptin is a protease produced by *Lactobacillus casei* which is able to degrade IP-10 (CXCL10), a proinflammatory molecule (Fig. 2). Based on this, lactocepin-producing probiotic species have been proposed to be of therapeutic use for IBD patients, while no clinical trials studied their application, probiotic use of *L. casei* DN-114 001 has proven effective against gastrointestinal inflammatory conditions.

Degradation of inhibitory cytokines, leading to increased activation of the immune system, is another method of interaction. Cgr2 is an enzyme produced by *E. lenta* that can convert digoxin, a cardiac medication, into an inactive molecule. Cgr2 also degrades RORγt inhibitors increasing levels of IL-17a (CTLA-8) and activating Th17 cells within mice, although the specific inhibitor degraded is currently unknown. This proinflammatory process can itself be inhibited via dietary arginine which appears
Stimulation of immune cells to enhance response to checkpoint inhibitors

The gut microbiome has been identified as a factor influencing host response to medication, such as checkpoint inhibitor (CPI) therapy. CPIs are a form of immunotherapy for treatment of cancer which target the immune escape mechanisms used by cancerous cells. There are three main target molecules that are inhibited: CTLA-4, PD-1, and PD-L1. The interaction between the microbiome and CPIs has been shown to be complex and is not limited to a single species, instead showing cohort-specific microbiome signatures.

Based on this, FMT has been used to modulate the microbiome of non-responders and improve CPI therapy. This was successful in 30% of patients (n = 10) treated with anti-PD-1 CPI therapy and further improved to 40% when using faecal material from responders. While the exact mechanism by which FMT improves anti-PD-1 response is undefined, the microbiome-dependent nature of CTLA-4 CPI therapy has been better characterised. B. fragilis and Bacteroides thetaiotaomicron were identified to be key for T cell priming, without which CTLA-4 blockade is ineffective (Fig. 2). Specifically, the zwitterionic polysaccharides found in the capsule of these species stimulates the immune response. Responders have also been confirmed to have significantly greater abundance of these taxa within their gut microbiome. Increasing the abundance of these species via application of microbiome-based interventions may improve response to CTLA-4 CPI, however, such methods should be targeted as other members of this genus (Bacteroides) are not beneficial to the host. Bacteroides intestinalis has been linked to toxicity during combined CPI therapy. This suggests the interactions between this genus of bacteria and the immune system are complex and require further study to ensure the best outcome for the patient.

Other members of the gut microbiome associated with clinical response to PD-1, and PD-L1 treatment are A. muciniphila and Enterococcus hirae. Germ-free mice gavaged with these species were observed to become responsive to PD-1 treatment. This may be in part due to stimulating the secretion of IL-12 by Dcs, Th1 cell reactivity to A. muciniphila, and Tc cell reactivity to A. muciniphila and E. hirae, however the exact mechanism remains unclear.

CONCLUSIONS

While microbiome-based interventions influence the host immune system using multiple ways, our understanding is still in its infancy and further work is needed to understand these mechanisms and utilise this information to design better intervention strategies. However, implementation of this information has already led to great advancements over a relatively short period of time and future advancements are likely to occur at a fast rate. In Box 2 we detail a few of the most exciting developments in recent and coming years. Additionally, while this review has focused on the bacterial and viral fractions of the microbiome, the fungal residents of the gut have also been identified as being important to host health and their potential use should be studied further.

REFERENCES

1. Li, X. V. et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 603, 672–678 (2022).
2. Forster, S. C. et al. A human gut bacterial genome and culture collection for improved metagenomic analyses. Nat. Biotechnol. 37, 186–192 (2019).
3. Naish, S. et al. Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome. Nat. Microbiol. 6, 960–970 (2021).
4. Beghini, F. et al. Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome. ISME J. 11, 2848–2863 (2017).
5. Karo-Aat, D. et al. Helminth-induced reprogramming of the stem cell compartment inhibits type 2 immunity. J. Exp. Med. 219, e20212311 (2022).
6. Zais, M. M. et al. The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic Inflammation. Immunity 43, 998–1010 (2015).
7. Groussin, M. et al. Elevated rates of horizontal gene transfer in the industrialized human microbiome. Cell 184, 2053–2067.e18 (2021).
8. Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 1, 1 (2019).
9. Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).
10. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
11. Schlossing, S. et al. Genomic variation landscape of the human gut microbiome. Nature 493, 45–50 (2012).
12. Podlesny, D. et al. Metagenomic strain detection with SameStr: identification of a persisting core gut microbiota transferable by fecal transplantation. Microbiome 10, 1–15 (2022).
13. De Filipps, F. et al. Distinct Genetic and Functional Traits of Human Intestinal Prevotella copri Strains Are Associated with Different Habitual Diets. Cell Host Microbe 25, 444–453.e3 (2019).
14. Thomas, A. M. & Segata, N. Multiple levels of the unknown in microbiome research. BMC Biol. 17–20 (2019).
15. Hitch, T. C. A. et al. Recent advances in culture-based gut microbiome research. Int. J. Med. Microbiol. 311, 151485 (2021).
16. Blaser, M. J. et al. Lessons learned from the prenatual microbiome controversy. Microbiome 9, 1–7 (2021).
17. Walter, J. & Honeft, M. W. A philosophical perspective on the prenatal in utero microbiome debate. Microbiome 9, 1–9 (2021).
18. de Gooffau, M. C. & et al. Human placenta has no microbiome but can contain potential pathogens. Nature 572, 329–334 (2019).
19. De Agüero, M. G. et al. The maternal microbiota drives early postnatal innate immune development. Science 351, 1296–1302 (2016).
20. Barlow, J. T. et al. Progesterone Increases Bifidobacterium Relative Abundance during Late Pregnancy. Cell Rep. 27, 730–736.e3 (2019).
21. Mitchell, C. M. et al. Delivery Mode Affects Stability of Early Infant Gut Microbiota. Cell Rep. Med. 1, 100156 (2020).
22. Cheng, M. & Ning, K. Stereotypes About Enterotype: the Old and New Ideas. Front. Cell. Infect. Microbiol. 9, 1680–1692.e7 (2021).
23. Miyauchi, E. et al. Analysis of colonic mucosa-associated microbiota using endoscopically collected lavage. Sci. Rep. 12, 1–8 (2022).
24. Collado, M. C., Derrien, M., Isolauri, E., De Vos, W. M. & Salminen, S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 73, 7767–7770 (2007).
25. Yang, Y. et al. Within-host evolution of a gut pathobiont facilitates liver transplantation. Nature 607, 563–570 (2022).
26. Yagi, S. et al. Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. Sci. Rep. 10, 1–12 (2020).
27. Mau, J. M. et al. Gastrointestinal pH and transit time profiling in healthy volunteers using the InteliCap system confirms ileo-colonic release of ColoPulse tablets. PloS One 10, 1–17 (2015).
28. Ciem, J. & et al. Primary Human Colonic Mucosal Barrier Crosstalk with Super-Oxygen-Sensitive Faecalbacterium prausnitzii in Continous. Curr. Med. 2, 74–98e9 (2021).
29. Watson, D. et al. Selective carbohydrate utilization by lactobacilli and bifido-bacteria. J. Appl. Microbiol. 114, 1132–1146 (2013).
30. Clausen, M. R., Bonnén, H. & Mortensen, P. B. Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. Gut 32, 923–928 (1991).
31. Rubino, F. et al. Divergent functional isoforms drive niche specialisation for nutrient acquisition and use in rumen microbiome. ISME J. 11, 932–944 (2017).
32. Tasse, L. et al. Functional metagenomics to mine the human gut microbiome for dietary fiber catabolic enzymes. Genome Res. 20, 1605–1612 (2010).
33. Jallil-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat. Biomed. Eng. 3, 520–531 (2019).
34. Albenberg, L. et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 147, 1055–1063.e8 (2014).
35. Lee, Y.-Y., Tsolis, R. M. & Baumler, A. J. The microbiome and gut homeostasis. Science 377, eabp9660 (2022).
36. Tang, Q. et al. Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices. Front. Cell. Infect. Microbiol. 10, 1–10 (2020).
37. Zhang, F., Luo, W., Shi, Y., Fan, Z. & Ji, G. Should we standardize the 1,700-year-old fecal microbiota transplantation. Am. J. Gastroenterol. 107, 1755 (2012).
38. Noord, E. et al. Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
39. Baunwall, S. M. D. et al. Faecal microbiota transplantation for recurrent Clostridiodes difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 29–30, 100642 (2020).
40. Okahara, K. et al. Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation. J. Clin. Med. 9, 1650 (2020).
41. Kump, P. et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment. Pharmacol. Ther. 47, 67–77 (2018).
42. Sokol, H. et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: A pilot randomized controlled study. Microbiome 8, 1–14 (2020).
43. Staley, C. et al. Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostrididium difficile Infection. MBio 10, 1–12 (2019).
44. Podlesny, D. et al. Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Rep. Med. 100711 https://doi.org/10.1016/j.cellrepmed.2022.100711 (2022).
45. Schmidt, T. S. et al. Drivers and Determinants of Stage Dynamics Following Faecal Microbiota Transplantation. bioRxiv 2021.09.30.246210 (2021).
46. Conceição-Neto, N. et al. Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC. Gut 67, 1558–1559 (2018).
47. Wilson, B. C. et al. Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. Microbiome 9, 1–16 (2021).
48. Olesen, S. W. & Gerardin, Y. Re-Evaluating the Evidence for Faecal Microbiota Transplantation ‘Super-Donors’ in Inflammatory Bowel Disease. J. Crohn’s Colitis 15, 453–461 (2021).
49. Duvallat, C. et al. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 14, 1–18 (2019).
50. Rintor, E. et al. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology 160, 158–173.e10 (2021).
51. Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Transl. Med. 10, eaap9489 (2018).
52. Suez, J. et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution is Impaired by Probiotics and Improved by Autologous FMT. Cell 174, 1406–1423.e16 (2018).
136. Martínez, I., Kim, J., Duffy, P. R., Schlegel, V. L. & Walter, J. Resistant stanches types 2 and 4 have different effects on the composition of the fecal microbiota in human subjects. PLoS One 5, e15046 (2010).

137. Vandeputte, D. et al. Prebiotic insulin-type fructans induce specific changes in the human gut microbiota. Gut 66, 1968–1974 (2017).

138. Davis, L. M. G., Martínez, I., Walter, J. & Hutkins, R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int. J. Food Microbiol. 144, 285–292 (2010).

139. Dehee, E. C. et al. Precision Microbiome Modulation with Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production. Cell Host Microbe 27, 389–404.e6 (2020).

140. Dobranowski, P. A. & Stintzi, A. Resistant starch, microbiome, and precision nutrition. Gut Microbes 13, 1926842 (2021).

141. Bendzik, Z. A., Knudsen, K. E. B., Keenan, M. J. & Maroco, M. L. Conserved and variable responses of the gut microbiome to resistant starch type 2. Nutr. Res. 77, 12–28 (2020).

142. Ze, X., Duncan, S. H., Louis, P. & Flint, H. J. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 6, 1535–1543 (2012).

143. Nguyen, N. K. et al. Gut microbiota modulation with long-chain com bran arabinoxylan in adults with overweight and obesity is linked to an individualized temporal increase in fecal propionate. Microbiome 8, 1–21 (2020).

144. Benitez-Pavez, A. et al. A Multi-omics Approach to Unraveling the Microbiome-Mediated Effects of Arabinoxylan Oligosaccharides in Overweight Humans. mSystems 4, 1–16 (2019).

145. Leitch, E. C. M. W., Walker, A. W., Duncan, S. H., Holtrop, G. & Flint, H. J. Selective colonization of insoluble substrates by human faecal bacteria. Environ. Microbiol. 9, 667–679 (2007).

146. Vandeputte, D. et al. Prebiotic inulin-type fructans induce speci...
Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nat. Med.* 25, 679–689 (2019).

Bernstein, C. et al. Carcinogenicity of deoxycholate, a secondary bile acid. *J. Natl. Cancer Inst.* 88, 863–871 (1996).

Ege, M. J. et al. Exposure to Environmental Microorganisms and Childhood Immunology: Lessons from Human Microbiota-Associated Conditions. *Curr. Opin. Immunol.* 23, 111595 (2021).

Lamas, B., Nairnald, J. M. & Sokol, H. Aryl hydrocarbon receptor and intestinal immunity review-article. *Mucosal Immunol.* 11, 1024–1038 (2018).

Laursen, M. F. et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. *Nat. Microbiol.* 6, 1367–1382 (2021).

Azad, M. B. et al. Breastfeeding, maternal asthma and wheezing in the first year of life: a longitudinal birth cohort study. *Eur. Respir. J.* 49, 1602091 (2017).

Ley, D. et al. Early life nutrition influences susceptibility to chronic inflammatory colitis in later life. *Sci. Rep.* 9, 1–15 (2019).

Klu, R. et al. Bifidobacterium breve UCC2003 Induces a Distinct Global Transcriptomic Program in Neonatal Murine Intestinal Epithelial Cells. *iScience* 23, 101336 (2020).

Robertson, C. et al. Incidence of necrotising enterocolitis before and after introducing routine prophylactic Lactobacillus and Bifidobacterium probiotics. *Arch. Dis. Child. Fetal Neonatal Ed.* 105, 380–386 (2020).

Tobia, J. et al. Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants. *J. Pediatr.* 244, 64–71.e2 (2022).
Koppel, N., Bisanz, J. E., Pandelia, M., Turnbaugh, P. J. & Balskus, E. P. Discovery of a new gut microbiome member. *Nature*, 266, 1067–1080.e16 (2020).

Alexander, M. et al. Human gut bacterial metabolism drives Th17 activation and promotes checkpoint inhibitor refractoriness. *Nature*, 359, 1079–1080.15 (2018).

Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. *Nature*, 359, 1079–1080.e16 (2020).

Hörmannsperger, G., Schillde, M., Avon & Haller, D. Lactocepin as a protective factor against spontaneous colon cancer. *Nature*, 245, 276–282 (2003).

Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nature*, 238, 276–282 (2003).

Meyer, F. et al. Propionate supplementation promotes the expansion of peripherally regulatory T-cells in patients with end-stage renal disease. *J. Nephrol.*, 33, 817–827 (2020).

Nagata, C. et al. Supplementation of short-chain fatty acid, sodium propionate, in patients on maintenance—beneficial effects on inflammatory parameters and gut-derived uremic toxins—a pilot study (Plan study). *J. Clin. Med.*, 7, 315 (2018).

Duscha, A. et al. Prospionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. *Cell*, 180, 1067–1080.e16 (2020).

Sjöqvist, U. et al. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysbiosis. *Gastroenterology*, 149, 950–977 (2010).

Pols, T. W. H. et al. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. *PloS One*, 12, 1–16 (2017).

Monteleone, I. et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. *Gastroenterology*, 141, 237–248.e1 (2011).

Lee, J. S. et al. AHR drives the development of gut ILC2 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. *Nat. Immunol.*, 13, 144–152 (2012).

Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nat. Med.*, 22, 598–605 (2016).

Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Gastroenterology*, 39, 372–385 (2013).

Schillde, M. A. Von et al. Lactobacilli secreted by Lactobacilli exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. *Cell Host Microbe*, 11, 367–392 (2012).

Hörmannsperger, G., Schillde, M. Avon & Haller, D. Lactocepin as a protective microbial structure in the context of IBD. *Gastroenterology*, 141, 237–248.e1 (2011).

Llopis, M. et al. Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease murine. *Inflamm. Bowel Dis.*, 15, 275–283 (2009).

Koppel, N., Bisanz, J. E., Pandelia, M., Turnbaugh, P. J. & Balskus, E. P. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. *Elife*, 7, 1–32 (2018).

Alexander, M. et al. Human gut bacterial metabolism drives Th17 activation and colitis. *Cell Host Microbe*, 30, 17–30.e9 (2022).

Haifer, C. et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. *J. Infect. Dis.*, 213, 1432–1438 (2020).

Oh, J. Z. et al. TLR5-mediated sensing of gut microbiota is necessary for anti-viral innate responses in the developing murine gut. *Cell*, 180, 165–175 (2022).

Steiner, H. E. et al. Role of the gut microbiota in cardiovascular disease: A European prospective multi-centre cohort study (EPIC-BID). *J. Crohn’s Colitis*, 12, 129–136 (2018).

Décérolle, P. et al. The probiotic strain H alvea h4597* improves weight loss in overweight subjects under moderate hypocaloric diet: A proof-of-concept, multicenter randomized, double-blind placebo-controlled study. *Nutrients*, 13, 1–4 (2021).

Kravchychyn, A. C. P. et al. The Long-Term Impact of High Levels of Alpha-Melanocyte-Stimulating Hormone in Energy Balance among Obese Adolescents. *Ann. Nutr. Metab.*, 72, 279–286 (2018).

Hempel, S. et al. Infections: From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. *Gastroenterology*, 149, 110–118.e4 (2015).

Hafner, C. et al. Lypophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. *Jancer Gastroenterol. Hepatol.*, 7, 141–151 (2022).

Oliphant, K. et al. Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria In Vivo. *mSystems*, 5, e00404-19 (2020).

Ma, J. et al. Comparison of gut microbiota in exclusively breast-fed and formula-fed babies: a study of 91 term infants. *Sci. Rep.*, 10, 1–11 (2020).

Chichilovski, M., De Langtigue, G., Bruce German, J., Raybould, H. E. & Mills, D. A. Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affects intestinal epithelial function. *J. Pediatr. Gastroenterol. Nutr.*, 55, 321–327 (2012).

Gehrig, J. L. et al. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. *Science*, 365, eaau4732 (2019).

Chen, R. Y. et al. A Microbiota-Directed Food Intervention for Undernourished Children. *N. Engl. J. Med.*, 384, 1517–1528 (2021).

Zeevi, D. et al. Personalized Nutrition by Prediction of Glycemic Responses. *Cell*, 163, 1079–1095 (2015).

Tomasi, M. et al. Commensal bifidobacteria strains enhance the efficacy of neo-epitope based cancer vaccines. *Vaccines*, 9, 1–19 (2021).

OH, J. Z. et al. TLRS-mediated sensing of gut microbiota is necessary for anti-body responses to seasonal influenza vaccination. *Immunity*, 41, 478–492 (2014).

Koonezheim, M. et al. Development of therapeutic drugs by human gut bacteria. *Nature*, 597, 533–538 (2021).

Steiner, H. E. et al. Role of the gut microbiome in cardiovascular drug response: The potential for clinical application. *Pharmacotherapy*, 42, 165–176 (2022).

Rouanet, A. et al. Live Biotherapeutic Products, A Road Map for Safety Assessment. *Front. Med.*, 7, 1–13 (2020).

Olle, B. Medicines from microbiota. *Nat. Biotechnol.*, 31, 309–315 (2013).

Fabienne Kur et al. Co-cultivation is a powerful approach to produce a robust functionally designed synthetic consortium as a live biotherapeutic product (LBP). *bioRxiv* https://doi.org/10.1101/2021.10.13.464188v1 (2021).

Ducarmon, Q. R., Kuijper, E. J. & Olle, B. Opportunities and challenges in development of live biotherapeutic products to functionally designed synthetic consortium as a live biotherapeutic product. *Front. Cell. Infect. Microbiol.*, 9, 341 (2019).

Steiner, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. *Science*, 289, 1352–1355 (2000).

Kim, K. et al. Engineering Bacteroides thetaiotaomicron to produce non-native butyrate based on a genome-scale metabolic model-guided design. *Metab. Eng.*, 68, 174–186 (2021).

Kumar, N., Hitch, C. A., Haller, D., Lagkovardos, I. & Clavel, T. MiMIC: a bioinformatic approach for generation of synthetic communities from metagenomes. *Microb. Biotechnol.* https://doi.org/10.1111/1751-7915.13845 (2021).

Shepherd, E. S., DeLoache, W. C., Pruss, K. M., Whitaker, W. R. & Sonnenburg, J. L. An exclusive metabolic niche enables strain engrafment in the gut microbiota. *Nature* https://doi.org/10.1038/s41586-017-0092-4 (2018).
ACKNOWLEDGEMENTS
Figures were created in BioRender.

AUTHOR CONTRIBUTIONS
T.C.A.H. and T.C. initiated the review, detailing manuscript structure and defined its content. All authors contributed to drafting text sections and provided comments on the structure and overall content. T.C.A.H. coordinated the writing process. All authors reviewed the final version and agreed with its content.

FUNDING
Open Access funding enabled and organized by Projekt DEAL. T.C.A.H. and T.C. received funding from the DFG (German Research Foundation): project-ID 403224013 (SFB 1382).

COMPETING INTERESTS
T.C.A.H. and T.C. have ongoing scientific collaborations with HiPP GmbH. T.C. is also a member of the scientific advisory board of Savanna Ingredients GmbH.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Thomas Clavel.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.